上海医药2024，Vol.45Issue(3) ：25-27,54.

静脉用质子泵抑制剂使用合理性分析及院内管控

Analysis of the reasonability of the use of intravenous proton pump inhibitors and its in-hospital control

庞立峰 华素
上海医药2024，Vol.45Issue(3) ：25-27,54.
✕
  • 维普
  • 万方数据

静脉用质子泵抑制剂使用合理性分析及院内管控

Analysis of the reasonability of the use of intravenous proton pump inhibitors and its in-hospital control

庞立峰 1华素1
扫码查看

作者信息

  • 1. 南阳市第一人民医院药学部 南阳 473010
  • 折叠

摘要

目的:探讨我院静脉用质子泵抑制剂(PPIs)使用的合理性.方法:收集 2022 年度我院使用PPI的病例,共 226 份病历资料符合要求.结果:进入季度使用金额排名前五名次数最多的PPIs依次是注射用艾司奥美拉唑、注射用艾普拉唑、注射用雷贝拉唑、注射用奥美拉唑;病历不合理率为 64.16%,无适应证用药 53 例(36.55%),用法用量不适宜 46例(31.72%),疗程不适宜 21例(14.48%),遴选药品不适宜 17例(11.72%),联合用药不适宜 5例(3.45%),溶媒不适宜3 例(2.07%).结论:对PPI使用不合理的现象需要加强重点品种管控,提升医师的合理用药水平,促进合理用药.

Abstract

Objective:To investigate the reasonability of the use of intravenous proton pump inhibitors(PPIs)in our hospital.Methods:The cases using PPIs in our hospital in 2022 were collected,and a total of 226 medical records met the requirements.Results:The PPI injections with the highest number of times listed in the top five quarterly amounts were in order esomeprazole,eprazole,rabeprazole and omeprazole.The unreasonable rate in the 226 medical records accounted for 64.16%,of which 53 cases(36.55%)were used without indications,46 cases(31.72%)were not suitable for dose,21 cases(14.48%)were not suitable for the course of treatment,and 17 cases were not suitable for drug selection(11.72%),5 cases(3.45%)were not suitable for combination,3 cases(2.07%)were not suitable for solvent.Conclusion:The phenomenon of unreasonable use of PPIs requires strengthening the control of key varieties and improving the level of rational medication among physicians so as to promote rational medication.

关键词

质子泵抑制剂/合理用药/管控

Key words

proton pump inhibitors/rational drug use/management and control

引用本文复制引用

基金项目

南阳市科技攻关计划项目(KJGG007)

出版年

2024
上海医药
上海医药行业协会

上海医药

影响因子：0.781
ISSN：1006-1533
参考文献量14
段落导航相关论文